X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The collaboration with Pfizer to evaluate atirmociclib, selective-CDK4 inhibitor, in combination with RLY-2608 and fulvestrant in patients with PI3Kα-mutated, HR+, HER2- metastatic breast cancer.
Lead Product(s): RLY-2608,Atirmociclib,Fulvestrant
Therapeutic Area: Oncology Product Name: RLY-2608
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Pfizer Inc
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration June 05, 2024
Details:
Relay Therapeutics expects to use net proceeds to advance RLY-2608, , a first-in-class mutant-selective allosteric PI3Ka inhibitor that decouples anti-tumor activity from hyperinsulinemia, towards registrational trial.
Lead Product(s): RLY-2608,Fulvestrant,Palbociclib
Therapeutic Area: Oncology Product Name: RLY-2608
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Nextech
Deal Size: $30.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement January 08, 2024
Details:
Under the collaboration, Relay Therapeutics utilized X-Chem’s DNA-Encoded Library platform to perform hit finding intended to discover molecules with differentiated pharmacological properties.
Lead Product(s): Undisclosed
Therapeutic Area: Technology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Small molecule
Recipient: X-Chem
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration December 05, 2023
Details:
RLY-4008 (lirafugratinib) is a potent, selective and oral small molecule inhibitor of FGFR2, a receptor tyrosine kinase that is frequently altered in certain cancers and demonstrated FGFR2-dependent killing in cancer cell lines and induced regression in in vivo models.
Lead Product(s): RLY-4008
Therapeutic Area: Oncology Product Name: RLY-4008
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 12, 2023
Details:
RLY-4008 is a potent, selective and oral small molecule inhibitor of FGFR2, a receptor tyrosine kinase that is frequently altered in certain cancers and demonstrated FGFR2-dependent killing in cancer cell lines and induced regression in in vivo models.
Lead Product(s): RLY-4008
Therapeutic Area: Oncology Product Name: RLY-4008
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 25, 2023
Details:
RLY-2608 is a selective inhibitors of PI3K alpha. PI3K alpha is the most frequently mutated in all cancers, with oncogenic mutations detected in about 13% of patients with solid tumors. RLY-2608 is currently being evaluated for advanced solid tumors with a PIK3CA mutation.
Lead Product(s): RLY-2608,Fulvestrant
Therapeutic Area: Oncology Product Name: RLY-2608
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 18, 2023
Details:
RLY-2608 is a selective inhibitors of PI3K alpha. PI3K alpha is the most frequently mutated in all cancers, with oncogenic mutations detected in about 13% of patients with solid tumors. RLY-2608 is currently being evaluated for advanced solid tumors with a PIK3CA mutation.
Lead Product(s): RLY-2608,Fulvestrant
Therapeutic Area: Oncology Product Name: RLY-2608
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 06, 2023
Details:
RLY-4008 demonstrated 88% overall response rate (15 out of 17) from interim data of pan-FGFR treatment (FGFRi)-naïve FGFR2-fusion cholangiocarcinoma (CCA) patients treated at the pivotal dose.
Lead Product(s): RLY-4008
Therapeutic Area: Oncology Product Name: RLY-4008
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 11, 2022
Details:
RLY-4008 is a potent, selective and oral small molecule inhibitor of FGFR2, a receptor tyrosine kinase that is frequently altered in certain cancers,demonstrated FGFR2-dependent killing in cancer cell lines and induced regression in vivo models.
Lead Product(s): RLY-4008
Therapeutic Area: Oncology Product Name: RLY-4008
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 18, 2022
Details:
Under the collaboration, Genentech will assume development of RLY-1971 with the potential to expand into multiple combination studies including with Genentech’s investigational inhibitor of KRAS G12C, GDC-6036.
Lead Product(s): RLY-1971,GDC-6036
Therapeutic Area: Oncology Product Name: RLY-1971
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Genentech
Deal Size: $795.0 million Upfront Cash: $75.0 million
Deal Type: Collaboration December 14, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
